Tidutamab
More
Less
Tidutamab Usage And Synthesis
Uses
Tidutamab (XmAb-18087) is a humanized and affinity-optimized bispecific antibody (bsAb) targeting SSTR2 binding domain and T-cell binding domain (CD3). Tidutamab possesses a full Fc domain to maintain long serum half-life.Tidutamab eliminates SSTR+ tumor cells by stimulating redirected T cellmediated cytotoxicity (RTcC)[1].
in vivo
Tidutamab (XmAb-18087; 3 mg/kg; i.p.; single dose) stimulates human T cell killing of SSTR2+ A549 lung carcinoma tumors in NSG mice[1].
| Animal Model: | NSG mice[1] |
| Dosage: | 3 mg/kg |
| Administration: | Intraperitoneal injection; single dose |
| Result: | lnduced anti-tumor activity in human PBMC-engrafted NSG mice. |
References
[1] Hyung LS, et, al. Anti-SSTR2 × anti-CD3 bispecific antibody induces potent killing of human tumor cells?in vitro?and in mice, and stimulates target-dependent T cell activation in monkeys: A potential immunotherapy for neuroendocrine tumors. Cancer Res?(2017) 77 (13_Supplement): 3633.
TidutamabSupplier
ShangHai Biochempartner Co.,Ltd
- Tel
- 177-54423994 17754423994
- 2853530910@QQ.com
TargetMol Chemicals Inc.
- Tel
- +1-781-999-5354; +17819995354
- marketing@targetmol.com
Wuhan Chemstan Biotechnology Co., Ltd.
- Tel
- 027-65317797 15926423062
- 422450190@qq.com
TargetMol Chemicals Inc.
- Tel
- 4008200310
- marketing@tsbiochem.com
Biolab Reagents
- Tel
- 027-65279366 18108604356
- products@biolabreagent.com